Law360, New York (September 08, 2009) -- Cadence Pharmaceuticals Inc. has registered for an aggregate initial offering of up to $100 million in securities with the U.S. Securities and Exchange Commission.
The offering allows for a combination of debt securities, preferred and common stock, debt warrants and equity warrants. It extends the company's window for selling securities and gives more flexibility...
